Top Qs
Timeline
Chat
Perspective
Valneva SE
Franco-austrian vaccine company From Wikipedia, the free encyclopedia
Remove ads
Valneva SE is a specialty vaccine company registered in Saint-Herblain, France, developing, producing and commercializing vaccines for infectious diseases. It has manufacturing sites in Livingston, Scotland; Solna, Sweden, and Vienna, Austria; with other offices in France, Canada and the United States.[1][2][3]
 | This article may have been created or edited in return for undisclosed payments, a violation of Wikipedia's terms of use. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. (August 2025) |
Remove ads
Background
Valneva was founded in 2013 through the merger of Austrian company Intercell and French company Vivalis SA.[4][5] It has been listed since May 2013 on Euronext Paris Paris and since May 2021 on the US Nasdaq {{cite news |url=https://https://www.globenewswire.com/news-release/2021/05/06/2224042/0/en/Valneva-Announces-the-Pricing-of-its-Initial-Public-Offering-on-Nasdaq.html%7C. Valneva used to be listed on the Vienna Stock Exchange.[citation needed]
Remove ads
Products
Summarize
Perspective
Marketed vaccines
Vaccines marketed by Valneva include Ixiaro, a vaccine against Japanese encephalitis (approved in Europe, America and Australia)[6] Dukoral, a vaccine against cholera and LT-ETEC (approved in Europe, Canada and Australia) and IXCHIQ, a vaccine against the chikungunya virus (live-attenuated, single-dose).[7]
Failed developments
Some of its candidates have failed in clinical trials: VLA43, a therapeutic vaccine against Pseudomonas aeruginosa,[8] V710, a therapeutic vaccine against Staphylococcus aureus (in collaboration with Merck),[9] and IC41, therapeutic vaccine against hepatitis C.[10]
COVID-19 vaccine
Valneva along with Dynavax Technologies[11] developed a candidate inactivated whole virus vaccine against COVID-19, VLA2001,[12] derived from its Ixiaro Japanese encephalitis vaccine, which underwent a Phase 1/2 trial in the United Kingdom.[13][14] The Phase 1/2 trial had 150 participants, testing three dose levels for safety, tolerability, and immunogenicity. The trial was expected to be complete by 15 February 2021, with full reporting completed by August 2021.[15]
Valneva and dynavax technologies[16] had reached an agreement with the UK government to provide up to 100 million doses to be manufactured at its facility in Livingston, Scotland. The UK government pre-ordered 60 million doses.[12][13] The trials were supported by the UK National Institute for Health Research and four British universities.[15] Due to government support, Valneva would progress immediately into Phase 3 trials and develop production capacity before the full evaluation of the Phase 1/2 trial, rather than the traditional slower sequential approach which has lower financial risk.[17]
The company manufacturing facility in Livingston, Scotland produces the VLA2001 vaccine.[18][19]
In September 2021, Valneva announced that the UK government had cancelled their vaccine order.[20] The cancellation reason was not officially given, but seemed to be related to difficulties getting building materials due to Brexit[21] and not vaccine quality.
On 14 April 2022, the UK Medicines and Healthcare products Regulatory Agency (MHRA) approved the vaccine, being the first in the world to do so.[22]
On 17 May 2022 the European Commission cancelled its advance purchase agreement for the vaccine which would have seen Valneva provide 60 million doses over two years.[23]
Remove ads
References
External links
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads